Belgian biotech ThromboGenics (Euronext Brussels: THR) is scrapping its Phase II CIRCLE study of THR-409 (ocriplasmin), as not enough patients have signed up.
In Brussels, as investors reacted bearishly to the announcement, the company’s share price dropped nearly a fifth in morning trading.
The trial was planned to investigate the candidate for non-proliferative diabetic retinopathy (NPDR).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze